Oncology Biosimilars Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others), By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: O9398A8A5C4CEN
TechSci Research

Abstracts

The Global Oncology Biosimilars Market, valued at USD 4.54 Billion in 2024, is projected to experience a CAGR of 6.94% to reach USD 6.79 Billion by 2030. Oncology biosimilars are biological products demonstrably highly similar to an approved original oncology biological product, exhibiting no clinically meaningful differences regarding safety, purity, and potency. The market's expansion is fundamentally driven by the increasing global incidence of various cancer types and the impending patent expiration of numerous blockbuster oncology biologics, which creates opportunities for lower-cost alternatives.

Key Market Drivers

The increasing global incidence of cancer serves as a primary catalyst for the oncology biosimilars market, generating substantial demand for effective yet affordable treatment solutions. As the worldwide cancer burden rises, healthcare systems are compelled to seek cost-efficient therapeutic alternatives to manage growing patient populations and control expenditures. This rising prevalence directly drives the necessity for accessible oncology therapies, with biosimilars playing a pivotal role in expanding treatment access.

Key Market Challenges

A significant challenge impeding the broader expansion of the Global Oncology Biosimilars Market is the substantial investment and intricate scientific expertise required for biosimilar development and manufacturing processes, alongside the necessity for extensive regulatory validation. This inherent complexity and considerable financial outlay directly deter potential manufacturers and prolong the market entry of oncology biosimilar products. The development pathway demands rigorous analytical characterization, preclinical evaluation, and clinical trials to establish biosimilarity to the original biologic, which is both capital-intensive and time-consuming.

This challenging development environment limits the number of pharmaceutical companies capable of undertaking such programs, especially for complex oncology biologics. Consequently, many reference products, even after patent expiration, do not face biosimilar competition.

Key Market Trends

The growing acceptance and trust in clinical settings significantly influences the global oncology biosimilars market by fostering greater confidence among healthcare professionals and patients. This increased assurance directly translates into higher adoption rates for biosimilar treatments. According to the Association for Accessible Medicines, biosimilar medicines generated $20.2 billion in savings in 2024 alone, highlighting their crucial economic value which underpins broader acceptance. Furthermore, a survey conducted on behalf of the Alliance for Safe Biologic Medicines in August 2024, revealed that 88% of physicians agree switching studies enhance their confidence in the safety of transitioning patients from an originator medicine to an interchangeable biosimilar. This robust physician confidence is paramount for overcoming historical skepticism and driving market penetration.

Key Market Players

• Teva Pharmaceuticals Industries Ltd.
• STADA Arzneimittel AG
• Shanghai Henlius Biotech, Inc.
• Sandoz Group AG
• Samsung Bioepis NL B.V.
• Pfizer Inc.
• Ligand Pharmaceuticals Inc.
• Mylan Inc.
• Innovent Biologics (USA), Inc.
• Celltrion Inc.

Report Scope:

In this report, the Global Oncology Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Oncology Biosimilars Market, By Drug Class:
• Monoclonal Antibodies
• G-CSF
• Hematopoietic Agents
• Others
• Oncology Biosimilars Market, By Type of Cancer:
• Breast Cancer
• Lung Cancer
• Stomach Cancer
• Prostate Cancer
• Cervical Cancer
• Blood Cancer
• Brain Cancer
• Others
• Oncology Biosimilars Market, By Distribution Channel:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Oncology Biosimilars Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oncology Biosimilars Market.

Available Customizations:

Global Oncology Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ONCOLOGY BIOSIMILARS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
  5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
  5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  5.2.4. By Region
  5.2.5. By Company (2024)
5.3. Market Map

6. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Drug Class
  6.2.2. By Type of Cancer
  6.2.3. By Distribution Channel
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Oncology Biosimilars Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Drug Class
      6.3.1.2.2. By Type of Cancer
      6.3.1.2.3. By Distribution Channel
  6.3.2. Canada Oncology Biosimilars Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Drug Class
      6.3.2.2.2. By Type of Cancer
      6.3.2.2.3. By Distribution Channel
  6.3.3. Mexico Oncology Biosimilars Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Drug Class
      6.3.3.2.2. By Type of Cancer
      6.3.3.2.3. By Distribution Channel

7. EUROPE ONCOLOGY BIOSIMILARS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Drug Class
  7.2.2. By Type of Cancer
  7.2.3. By Distribution Channel
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Oncology Biosimilars Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Drug Class
      7.3.1.2.2. By Type of Cancer
      7.3.1.2.3. By Distribution Channel
  7.3.2. France Oncology Biosimilars Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Drug Class
      7.3.2.2.2. By Type of Cancer
      7.3.2.2.3. By Distribution Channel
  7.3.3. United Kingdom Oncology Biosimilars Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Drug Class
      7.3.3.2.2. By Type of Cancer
      7.3.3.2.3. By Distribution Channel
  7.3.4. Italy Oncology Biosimilars Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Drug Class
      7.3.4.2.2. By Type of Cancer
      7.3.4.2.3. By Distribution Channel
  7.3.5. Spain Oncology Biosimilars Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Drug Class
      7.3.5.2.2. By Type of Cancer
      7.3.5.2.3. By Distribution Channel

8. ASIA PACIFIC ONCOLOGY BIOSIMILARS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Drug Class
  8.2.2. By Type of Cancer
  8.2.3. By Distribution Channel
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Oncology Biosimilars Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Drug Class
      8.3.1.2.2. By Type of Cancer
      8.3.1.2.3. By Distribution Channel
  8.3.2. India Oncology Biosimilars Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Drug Class
      8.3.2.2.2. By Type of Cancer
      8.3.2.2.3. By Distribution Channel
  8.3.3. Japan Oncology Biosimilars Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Drug Class
      8.3.3.2.2. By Type of Cancer
      8.3.3.2.3. By Distribution Channel
  8.3.4. South Korea Oncology Biosimilars Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Drug Class
      8.3.4.2.2. By Type of Cancer
      8.3.4.2.3. By Distribution Channel
  8.3.5. Australia Oncology Biosimilars Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Drug Class
      8.3.5.2.2. By Type of Cancer
      8.3.5.2.3. By Distribution Channel

9. MIDDLE EAST & AFRICA ONCOLOGY BIOSIMILARS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Drug Class
  9.2.2. By Type of Cancer
  9.2.3. By Distribution Channel
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Oncology Biosimilars Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Drug Class
      9.3.1.2.2. By Type of Cancer
      9.3.1.2.3. By Distribution Channel
  9.3.2. UAE Oncology Biosimilars Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Drug Class
      9.3.2.2.2. By Type of Cancer
      9.3.2.2.3. By Distribution Channel
  9.3.3. South Africa Oncology Biosimilars Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Drug Class
      9.3.3.2.2. By Type of Cancer
      9.3.3.2.3. By Distribution Channel

10. SOUTH AMERICA ONCOLOGY BIOSIMILARS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Drug Class
  10.2.2. By Type of Cancer
  10.2.3. By Distribution Channel
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Oncology Biosimilars Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Drug Class
      10.3.1.2.2. By Type of Cancer
      10.3.1.2.3. By Distribution Channel
  10.3.2. Colombia Oncology Biosimilars Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Drug Class
      10.3.2.2.2. By Type of Cancer
      10.3.2.2.3. By Distribution Channel
  10.3.3. Argentina Oncology Biosimilars Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Drug Class
      10.3.3.2.2. By Type of Cancer
      10.3.3.2.3. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL ONCOLOGY BIOSIMILARS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Teva Pharmaceuticals Industries Ltd.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. STADA Arzneimittel AG
15.3. Shanghai Henlius Biotech, Inc.
15.4. Sandoz Group AG
15.5. Samsung Bioepis NL B.V.
15.6. Pfizer Inc.
15.7. Ligand Pharmaceuticals Inc.
15.8. Mylan Inc.
15.9. Innovent Biologics (USA), Inc.
15.10. Celltrion Inc.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER